News | September 21, 2009

CardiacAssist Partners with Mentice to Showcase Transseptal Puncture Training Simulation

September 21, 2009 — CardiacAssist Inc. announced today that it will showcase transseptal puncture training simulation, developed by Mentice Inc., at its TandemHeart® System exhibit in San Francisco at the “Transcatheter Therapeutics (TCT) 2009” Annual Scientific Session next week. TandemHeart is the only 5 lpm net flow, percutaneous "extracorporeal circulatory support" device approved by the FDA for sale in the U.S. The TandemHeart device can be placed rapidly in a cath lab or an operating room—providing effective, reliable, temporary circulatory support for critically ill patients. TandemHeart is fully reimbursed by Medicare under existing DRG codes.

While transseptal puncture of the interatrial septum was introduced nearly 50 years ago, it remains a difficult procedure. Renewed interest in transseptal left heart catheterization is on the rise due to the development of left side catheter ablation and the emergence of percutaneous technologies to treat mitral and aortic valve disease. Indeed, the transseptal puncture technique has now been used in more than 1,500 TandemHeart cases by more than 300 physicians.

“We believe it is imperative for cardiologists to be knowledgeable about the transseptal puncture technique, and the Mentice training simulation is designed to show them how to perform a simple and safe transseptal puncture,” said CardiacAssist CEO Michael Garippa. “We are pleased to be partnering with Mentice to offer cardiologists the best simulation-training possible, and we expect to train more than 1,000 physicians as soon as possible to be ‘Tandem-ready’.”

“TCT 2009” will be held at the Moscone Convention Center in San Francisco, Sept. 21-25, 2009. CardiacAssist will be in booth number 2005 with information and displays pertaining to the TandemHeart System. Additionally, CardiacAssist will host a symposium—“Clinical Innovations and TandemHeart™ Support”—by invitation only on Thursday, Sept. 24th, from 6-8 p.m. at Morton’s Steak House, 400 Post Street.

The Symposium will feature presentations of cases that have saved patients’ lives at leading medical institutions across the country; presenters will include: Dr. Steven Burstein, Good Samaritan Hospital, Los Angeles; Dr. Kirk Garrett, Lenox Hill Hospital, New York City; and Dr. Srijoy Mahapatra, University of Virginia Health System, Charlottesville, Va. Current and prospective customers who are interested in attending the Symposium should visit CardiacAssist’s booth to receive an invitation.

To RSVP for the event, please contact Monica Bush at 412-963-7770, extension 247 or via email at [email protected]

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init